Secondary Prevention in Acute Coronary Syndromes: A CALIBER Study

Sponsor

University College, London (Other)

Overall Status

Unknown status

CT.gov ID

NCT01162187

Collaborator

Barts & The London NHS Trust (Other), University of Leicester (Other)

400,000

Enrollment

Duration (Months)

Study Details

Study Description

Brief Summary

All contemporary guidelines for secondary prevention in acute coronary syndromes recommend a combination of aspirin, beta-blockers, ACE-inhibitors and statins. Yet underutilisation of these drugs is common. We do not know in detail what drives underutilisation, nor what its long term consequences are for survival after discharge from hospital. Also unknown is whether potential adverse effects of underutilisation are the same for individual secondary prevention drugs.

This study will assess the impact of secondary prevention underutilisation on survival.

Condition or Disease	Intervention/Treatment	Phase
Acute Coronary Syndrome

Detailed Description

Using information from an England and Wales audit of acute coronary syndromes (the Myocardial

Ischaemia National Audit Project (MINAP)) we aim to assess:

(i) Survival from first time MINAP-registered event to death as a function of secondary prevention medications: To what degree do the effects of medications (assumed equal, independent and additive) relate to patient survival? Is there evidence of a differential effect of discharge medications? (ii) (a) Survival from first time MINAP-registered event to death or second time MINAP-registered event as a function of secondary prevention medications: To what degree do the effects of medications (assumed equal, independent and additive) relate to competing risks? Is there evidence of a differential effect of discharge medications? (b) Survival from first time MINAP-registered event to death or second time MINAP-registered phenotyped as STEMI, NSTEMI or Unstable Angina. To what degree do the effects of medications (assumed equal, independent and additive) relate to competing risks? Is there evidence of a differential effect of discharge medications? (iii) What impact would ensuring all medication is taken have on event free survival?

This study is part of the CALIBER (Cardiovascular disease research using linked bespoke studies and electronic records) programme funded over 5 years from the NIHR and Wellcome Trust. The central theme of the CALIBER research is linkage of the Myocardial Ischaemia National Audit Project (MINAP) with primary care (GPRD) and other resources. The overarching aim of CALIBER is to better understand the aetiology and prognosis of specific coronary phenotypes across a range of causal domains, particularly where electronic records provide a contribution beyond traditional studies. CALIBER has received both Ethics approval (ref 09/H0810/16) and ECC approval (ref ECC 2-06(b)/2009 CALIBER dataset).

Study Design

Study Type:

Observational

Anticipated Enrollment :

400000 participants

Observational Model:

Cohort

Time Perspective:

Retrospective

Official Title:

Secondary Prevention in Acute Coronary Syndromes: Long-term Survival in Relation to the Number and Combination of Evidence-based Therapies Prescribed Prior to Discharge (a CALIBER Study)

Study Start Date :

Jul 1, 2003

Anticipated Primary Completion Date :

Jun 1, 2010

Anticipated Study Completion Date :

Jun 1, 2010

Outcome Measures

Primary Outcome Measures

All cause mortality [Due to follow up an average of 3 years.]
Mortality as tracked by the Office for National Statistics

Secondary Outcome Measures

Competing risks between acute coronary syndrome phenotypes [Due to follow up an average of 3 years.]
Stable Angina, Unstable Angina, STEMI and NSTEMI will be treated both as startpoints and endpoints in transitions between phenotypes.